Between baseline and cycle 3 day 1, the patient had a 4.8-fold increase in plasma FGF-23 (a marker of FGFR inhibition) levels, which was accompanied by 30% reduction in target tumor size (Supplementary Fig. S3). The gene discussed is FGF23; the disease is neoplasm.